Pharmafile Logo
Pharmafocus logo
Advanced Search

Vigil Neuroscience

Showing 2 posts of 2 posts found.

sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

August 6, 2025
Mergers and Acquisitions Alzheimer's disease, Corporate, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology company specialising in neurodegenerative diseases. …

News
handshake

Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline

May 23, 2025
Mergers and Acquisitions, Research and Development Alzheimer's disease, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies for neurodegenerative diseases. The deal …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025